The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Sophia Humphreys, PharmD, MHA, BCBBS, discusses common barriers to cancer therapy and how care teams can assist patients in ...

Let us honor Gail Zeamer by ensuring that when a woman is told her mammogram might not be enough, she does not have to ...

Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory ...

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Get Q3 2025 insights from Novocure (NVCR): platform therapy expansion, profitability goals, earnings highlights, and cancer launch updates.

Researchers assessed variations in patterns of care and time to initial treatment for women diagnosed with breast, cervical, or ovarian cancer in various countries.

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A ...